ProCE Banner Activity

MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi

Slideset Download
Conference Coverage

Updated data from the phase III MOMENTUM trial show that momelotinib maintained symptom responses, transfusion independence, and spleen responses originally achieved by Week 24 through Week 48.

Released: December 12, 2022

Expiration: December 11, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen